BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• 

  Job Trends

  Hiring Outlook: Despite Challenges, January Brings Optimism for Job Market

  Most employers are expecting to hire this year, according to BioSpace data and Recruitment Manager Greg Clouse, who noted that companies are looking to do more than just replace people lost to turnover.

  February 6, 2025

   · 

  3 min read

   · 

  Angela Gabriel
• 

  Earnings

  AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations

  Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” deal for the pharma.

  February 6, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Layoffs

  X4 Pharmaceuticals Stumbles Again, Laying Off 30% of Workforce

  The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last year received FDA approval to treat WHIM syndrome, in the larger patient population with chronic neutropenia.

  February 6, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  Schizophrenia

  BMS’ Cobenfy Sales Begin, With Launch Full Speed Ahead

  Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the launch proceeding ahead of expectations.

  February 6, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Cancer

  Kura Eyes FDA Filing After Pivotal AML Win, but Investors Aren’t Impressed

  Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.

  February 6, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Viracta Winds Down Business, Unable to Weather Financial Troubles

  Viracta’s closure comes on the heels of its delisting from Nasdaq last month and multiple rounds of layoffs last year.

  February 6, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  BMS Adds $2B to Cost Cutting Plans, Eyes Deals After Cobenfy Success

  Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of exclusivity for its blockbuster drugs Eliquis and Opdivo.

  February 6, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Earnings

  After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’

  As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company has taken the GLP-1 supply chain too far.

  February 6, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• Press Releases

  Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

  February 6, 2025

   · 

  2 min read
• Press Releases

  Biopharmaceutical CMO and CRO Market Size to Worth USD 72.39 Bn by 2034

  February 6, 2025

   · 

  1 min read